Q-omics provides the consensus-scored FGF7P2 profile across patient tissues and cancer cell-line models. FGF7P2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FGF7P2 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, FGF7P2 RNA expression shows 5,784 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, LUSC, and STAD as cancer lineages where FGF7P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FGF7P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FGF7P2 survival associations across molecular data types. FGF7P2 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FGF7P2 RNA expression–survival associations across cancer types. High FGF7P2 expression shows unfavorable associations in HNSC, UVM, KIRP, KIRC and ACC, but favorable associations in SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for FGF7P2 RNA expression.
This table summarizes FGF7P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FGF7P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FGF7P2 shows lower tumor expression in LUSC and THCA. The LUSC box plot shows higher FGF7P2 RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p = .012).
This table shows molecular features associated with FGF7P2 in patient tissues and cancer cell lines. In patient samples, FGF7P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
